Saba Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Saba Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-270,751	Closed	-$2.71M	–	1005
2022 Q3	$2.71M	Hold	270,751	–	–	0.03%	604
2022 Q2	$2.68M	Hold	270,751	–	–	0.03%	629
2022 Q1	$2.67M	Buy	270,751 +214,300	+380%	+$2.1M	0.04%	545
2021 Q4	$551K	Buy	56,451 +29,577	+110%	+$290K	0.01%	622
2021 Q3	$263K	Buy	+26,874	New	+$262K	0.01%	486

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Saba Capital Management's EUCR Position: Q4 2022 in Review

Saba Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 270,751 shares — an estimated $2.71M sold.

Saba Capital Management first reported a position in EUCR in Q3 2021 and held it in 5 quarters. The position peaked at $2.71M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Saba Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Saba Capital Management sold 270,751 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $2.71M.
Saba Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2021 and held it in 5 quarters.
Saba Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $2.71M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Saba Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.